Philochem AG Announces Completion of Antitrust Clearance and Closing of the OncoACP3 Licensing Agreement with RayzeBio, a Bristol Myers Squibb Company, With a Potential Value of up to $1.35 Billion Plus Royalties

Otelfingen, Switzerland – 18 August 2025 – Philochem AG ("Philochem"), a wholly-owned subsidiary of Philogen company (MIL: PHIL), and RayzeBio, Inc. ("RayzeBio"), a wholly-owned subsidiary of Bristol-Myers Squibb company (NYSE: BMY), today announced the successful completion of U.S. antitrust review and the closing of the global licensing agreement for OncoACP3, a clinical-stage therapeutic and diagnostic agent targeting prostate cancer.

The transaction, initially announced on June 10, 2025, has now been finalized following clearance under the Hart–Scott–Rodino Antitrust Improvements Act of 1976 by the U.S. Federal Trade Commission (FTC). As part of the agreement, Philochem will receive an upfront payment of $350 million.

RayzeBio will be responsible for the development and any subsequent commercialization of OncoACP3. The license agreement also includes up to $1.0 billion in development, regulatory and commercial milestone payments, as well as mid-single to low double-digit royalties on global net sales.

"I am very pleased that we have received clearance, allowing us to proceed with this agreement with RayzeBio," said Dario Neri, CEO and CSO of Philogen. "They share our vision for revolutionizing the diagnosis and treatment of prostate cancer. We believe that OncoACP3 has all the credentials to become a breakthrough treatment for patients, translating scientific innovation into an important medical advance".

Ben Hickey, President, RayzeBio commented: "The closing of this agreement marks an important milestone for RayzeBio as we expand our leadership in the radiopharmaceuticals space. We look forward to advancing OncoACP3 for the benefit of patients, consistent with our strategy to bring forward best-in-class RPT candidates."

FOR MORE INFORMATION
Philogen – Investor Relations

IR@philogen.com - Emanuele Puca | Investor Relations

About Philogen group

Philogen is an Italian-Swiss group active in the biotechnology sector, specialised in the research and development of pharmaceutical products for the treatment of highly lethal diseases. Philogen's mission is to discover, develop and market innovative pharmaceuticals for the treatment of diseases of high unmet need. This is achieved by exploiting (i) proprietary technologies for the isolation of

ligands that react with antigens present in certain diseases, (ii) experience in the development of products targeted at the tissues affected by the disease, (iii) experience in drug manufacturing and development, and (iv) an extensive portfolio of patents and intellectual property rights. Although the Group's drugs are primarily oncology applications, the targeting approach is also potentially applicable to other diseases, such as certain chronic inflammatory diseases

Philochem AG
c/o ETH Zurich - Institute of Pharmaceutical Sciences
Wolfgang-Pauli-Str. 10 HCI E520 - CH-8093 Zurich, Switzerland
Tel: +41 44 633 78 67 - Fax: +41 44 633 14 81

MWST-Nr./VAT-REG: 664 749
Registration Nr. CH-020.3.030.226-7
Chart. Cap. CHF 2.830.000 Ent. Called up
www.philochem.ch - info@philochem.ch